Retatrutide is an investigational triple agonist peptide that activates GLP-1, GIP, and glucagon receptors. It's being developed by Eli Lilly for obesity and type 2 diabetes but is NOT yet approved for any use. It has shown unprecedented weight loss of up to 24% in Phase 2 trials.

Is retatrutide approved in the UK or EU?

No. Retatrutide is NOT approved anywhere in the world. It is an investigational compound currently in Phase 3 clinical trials. Regulatory submission is anticipated after Phase 3 completion, potentially in 2025-2026, with approval possibly following in 2026-2027 if trials are successful.

How does retatrutide compare to semaglutide and tirzepatide?

In Phase 2 trials, retatrutide showed the highest weight loss of any pharmaceutical agent: 24.2% vs ~22% for tirzepatide and ~17% for semaglutide. The addition of glucagon receptor activation appears to boost energy expenditure. However, Phase 3 data is needed to confirm these results.

Why is glucagon receptor activation beneficial for weight loss?

Despite glucagon raising blood sugar, it also increases energy expenditure (thermogenesis) and promotes fat oxidation. When combined with GLP-1 and GIP (which enhance insulin and suppress inappropriate glucagon), the net effect is enhanced weight loss while maintaining glucose control.

Can I buy retatrutide online?

NO. Any products sold online claiming to be retatrutide are unverified and likely counterfeit. Retatrutide is only available within clinical trials. Purchasing from unregulated sources is extremely dangerous—these products may contain unknown substances, incorrect doses, or nothing at all.

What are the risks of retatrutide?

Common side effects in trials included nausea, diarrhoea, vomiting, and constipation—similar to other incretin therapies. Long-term safety is unknown as only Phase 2 data exists. The effects of chronic glucagon receptor activation require further study. Only use within clinical trials.

When will retatrutide be available?

If Phase 3 trials are successful, Eli Lilly could submit for regulatory approval in 2025-2026, with potential approval in 2026-2027. However, clinical development timelines are uncertain and depend on trial outcomes. There is no guaranteed approval date.

How can I access retatrutide?

Currently, the only legitimate way to access retatrutide is through clinical trial participation. Visit ClinicalTrials.gov to search for TRIUMPH program trials in your area. Do not attempt to purchase from unregulated sources.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 25 September 2026

Corrected 25 September 2026: A study reference linked to an unrelated PubMed record. It now links to the correct paper (Sanyal et al., Nat Med 2024) and the summary has been rewritten to match that paper's abstract. An unsourced liver-fat figure elsewhere on this page has also been corrected to match the same trial data.

Share:X Post LinkedIn

GLP-1 Agonists•Updated 2026-09-25•7 min read

What Is Retatrutide? Benefits, Research & Safety

An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.

Share:X Post LinkedIn

Also known as:

LY3437943

Triple G

GGG agonist

BModerate human evidenceUK: Unlicensed (UK)WADA: Sport status unclear

UK summary: Investigational compound. Not yet a licensed UK medicine. Phase 2 human data are promising for weight loss but Phase 3 results and regulatory review are still required. Any 'retatrutide' offered for sale outside a registered clinical trial is grey-market.

Quick Facts

Overview

Retatrutide represents the cutting edge of incretin-based metabolic therapy, being a first-in-class triple agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Developed by Eli Lilly, it has shown unprecedented efficacy in Phase 2 clinical trials. While dual agonists like tirzepatide activated two receptors, retatrutide adds glucagon receptor activation—initially counterintuitive since glucagon raises blood sugar. However, glucagon also increases energy expenditure, promotes fat oxidation, and may reduce appetite independently of GLP-1. In the Phase 2 trial, retatrutide produced mean weight loss of 24.2% at the highest dose—exceeding all previous pharmaceutical interventions and rivalling outcomes of bariatric surgery. Approximately 26% of participants lost more than 30% of their body weight. **Critical Note:** Retatrutide is NOT approved for any use. It remains an investigational compound in clinical trials. Information here is for educational purposes about ongoing research. It should NOT be purchased from unregulated sources.

Evidence standards summary

Retatrutide — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

BModerate human evidenceOverall grade against our evidence grading methodology.

Investigational compound. Not yet a licensed UK medicine. Phase 2 human data are promising for weight loss but Phase 3 results and regulatory review are still required. Any 'retatrutide' offered for sale outside a registered clinical trial is grey-market.

02Human evidence grade

CLimited human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

BModerate human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
EU: NOT APPROVED. Investigational compound in Phase 3 clinical trials.
Notes: ⚠️ IMPORTANT: Retatrutide is NOT approved by any regulatory authority for any indication. It is currently in Phase 3 clinical trials. Any products sold online claiming to be retatrutide are likely counterfeit, unverified, and potentially dangerous. Do not purchase from unregulated sources.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

The most effective GLP-1 ever made — buy now before it's prescription-only.
Triple agonist means triple the fat loss in half the time.
Sold as 'research-grade retatrutide' identical to the Eli Lilly compound.
Safe for self-administration at home, no doctor needed.

07Common internet claims

Pre-launch access to the next-generation Mounjaro.
24% bodyweight loss guaranteed by 48 weeks.
Cheaper than waiting for the licensed version.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved by MHRA for weight loss”	E	No	High	Retatrutide is investigational and not licensed in the UK at the time of writing.
“Phase 2 trials showed ~24% weight loss”	B	Yes	Low	Phase 2 data show high mean weight loss; Phase 3 confirmation and regulatory review are required before clinical use.
“Available now from research peptide suppliers”	E	No	High	Any vendor selling 'retatrutide' is operating outside the regulated UK supply chain. Identity and purity are unverified.
“Safe to self-administer for personal use”	E	No	High	Long-term safety has not been established. Self-administration of an investigational compound carries serious risk.

09Safety uncertainty score

Very high

Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.

10Known adverse signals

Nausea, vomiting, diarrhoea, constipation, dyspepsia at trial doses.
Pancreatitis risk (class signal across incretin agonists).
Unknown chronic effects of sustained glucagon receptor activation.
Long-term cardiovascular and oncologic data not yet available.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

NOT APPROVED. Investigational compound. May be available only through clinical trial participation.

Read the full UK legal guide → Are peptides legal in the UK?

14EU legal position

NOT APPROVED. Investigational compound in Phase 3 clinical trials.

15What this page cannot tell you

Whether a vial sold online actually contains retatrutide rather than a relabelled tirzepatide or a placebo.
What the long-term safety profile looks like beyond the 48-week Phase 2 horizon.
How a grey-market compound interacts with insulin, sulfonylureas, or other glucose-lowering drugs.
Whether the manufacturing process matches sterile injectable standards.

16Last reviewed

Last reviewed: 25 September 2026

Next review due: 25 September 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Phase 3 outcomes (TRIUMPH programme) not yet published in full.
Cardiovascular outcome trial data pending.
Long-term safety of chronic glucagon receptor agonism unknown.
Real-world post-marketing surveillance impossible — drug is not licensed.

19Safer alternatives / established care pathways

Licensed Wegovy (semaglutide) via NHS or GMC-registered prescriber.
Licensed Mounjaro (tirzepatide) via NHS specialist or registered private clinic.
Enrolment in a registered TRIUMPH-programme Phase 3 trial via ClinicalTrials.gov.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What is the current MHRA status of retatrutide?
Are there any UK clinical trials I might be eligible for?
What licensed alternatives exist for my situation today (semaglutide, tirzepatide)?
Why is buying retatrutide from an online seller a risk even compared with other peptides?
How would suspected adverse events from any product be reported?

Discovery & History

Retatrutide's development builds on the success of tirzepatide and the scientific insight that glucagon, despite raising blood sugar, has metabolically beneficial effects that could be harnessed in combination with incretins. **Scientific Rationale:** **Glucagon's Dual Nature:** - Traditionally viewed negatively in diabetes (raises blood sugar) - However, glucagon also increases energy expenditure - Promotes hepatic fat oxidation - May suppress appetite independently - Combined with GLP-1, the glucose-raising effect can be offset **Development Timeline:** • **2018:** Eli Lilly begins development of triple agonist compounds • **2019:** LY3437943 (retatrutide) enters Phase 1 trials • **2022:** Phase 2 trial results presented showing unprecedented weight loss • **2023:** Phase 2 results published in New England Journal of Medicine • **2023-2024:** Phase 3 trials (TRIUMPH program) initiated • **2025-2026:** Phase 3 trials ongoing; regulatory submission anticipated **The Triple Agonist Concept:** Retatrutide was designed to combine: - GLP-1 effects: Appetite suppression, insulin secretion, glucose control - GIP effects: Enhanced insulin response, central appetite effects - Glucagon effects: Increased energy expenditure, fat oxidation The challenge was balancing these effects to maximise weight loss while maintaining glucose control—which the Phase 2 data suggests has been achieved.

Mechanism of Action

Retatrutide simultaneously activates three metabolic receptors, creating a comprehensive approach to energy balance: **GLP-1 Receptor Activation:** - Reduces appetite through hypothalamic signalling - Enhances glucose-dependent insulin secretion - Slows gastric emptying - Suppresses inappropriate glucagon secretion - Provides established metabolic benefits seen with semaglutide/tirzepatide **GIP Receptor Activation:** - Synergistic appetite suppression with GLP-1 - Enhanced insulin secretion - Potential direct effects on adipose tissue - Contributes to superior efficacy of dual/triple agonists **Glucagon Receptor Activation (The Novel Component):** This is what distinguishes retatrutide from tirzepatide: • **Increased Energy Expenditure:** Glucagon increases thermogenesis and basal metabolic rate, meaning more calories burned at rest. • **Enhanced Fat Oxidation:** Glucagon promotes breakdown of fat stores in the liver and adipose tissue for use as fuel. • **Hepatic Effects:** May improve fatty liver by promoting hepatic fat oxidation—potentially significant for NAFLD/NASH. • **Appetite Regulation:** Glucagon may have independent appetite-suppressing effects in the brain. • **Glucose Balance:** While glucagon raises blood sugar, the GLP-1 and GIP components provide sufficient insulin enhancement and glucagon suppression to maintain glucose control. **Net Effect:** The triple mechanism creates a metabolic state favouring weight loss from multiple angles: - Reduced energy intake (appetite suppression from GLP-1, GIP, glucagon) - Increased energy expenditure (glucagon's thermogenic effect) - Enhanced fat utilisation (glucagon's lipolytic effect) - Maintained glucose control (GLP-1/GIP insulin effects offset glucagon) [Diagram Placeholder: Triple receptor signalling pathways showing GLP-1, GIP, and glucagon receptor activation with effects on pancreas, liver, adipose tissue, and central nervous system]

Researched Benefits

Based on preclinical and clinical research findings:

1
Weight loss of 24.2% at highest dose in Phase 2—potentially the most effective pharmaceutical weight loss
2
26% of participants achieved ≥30% weight loss (matching surgical outcomes)
3
Significant reductions in liver fat (up to 82% relative reduction from baseline at 24 weeks in a MASLD substudy; 86% of participants at the highest dose reached normal liver fat)
4
Substantial improvements in glycaemic control in participants with diabetes
5
Marked reductions in waist circumference
6
Improvements in blood pressure and lipid profiles
7
High proportion achieving metabolically healthy weight status
8
Potential disease-modifying effects on NAFLD/NASH
9
Maintained glucose control despite glucagon agonism

Claim vs Evidence

How popular claims about Retatrutide stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved by MHRA for weight loss”	E	No	High	Retatrutide is investigational and not licensed in the UK at the time of writing.
“Phase 2 trials showed ~24% weight loss”	B	Yes	Low	Phase 2 data show high mean weight loss; Phase 3 confirmation and regulatory review are required before clinical use.
“Available now from research peptide suppliers”	E	No	High	Any vendor selling 'retatrutide' is operating outside the regulated UK supply chain. Identity and purity are unverified.
“Safe to self-administer for personal use”	E	No	High	Long-term safety has not been established. Self-administration of an investigational compound carries serious risk.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Phase 2 studied doses up to 12mg weekly; exact dosing for approval TBD
Frequency	Once weekly subcutaneous injection (in trials)
Duration	Phase 2 was 48 weeks; long-term data awaited from Phase 3
Notes	⚠️ RETATRUTIDE IS NOT APPROVED FOR ANY USE. It is an investigational compound in Phase 3 clinical trials. The information above is from research publications and does not represent prescribing guidance. Do NOT attempt to obtain retatrutide from unregulated sources.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (investigational—once weekly in trials)

Half-Life	Stability
Approximately 6 days (estimated from Phase 2 data)	Not applicable—investigational compound not commercially available

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (most common, similar to other incretin therapies)
Diarrhoea
Vomiting
Constipation
Decreased appetite
Dyspepsia
Abdominal pain
Injection site reactions

Rare Risks & Concerns

Pancreatitis (theoretical risk with all incretin therapies)
Gallbladder disease (accelerated by rapid weight loss)
Thyroid C-cell tumours (theoretical—class warning)
Unknown long-term risks (limited Phase 2 data)
Potential cardiovascular effects (being evaluated in trials)
Unknown effects of chronic glucagon receptor activation

Contraindications

This is an INVESTIGATIONAL compound—not approved for any use
Should only be used within clinical trial settings
Presumed contraindications similar to GLP-1 agonists:
- Personal/family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy and breastfeeding
- Type 1 diabetes
- History of pancreatitis

UK & EU Regulatory Context

🇬🇧 United Kingdom

NOT APPROVED. Investigational compound. May be available only through clinical trial participation.

🇪🇺 European Union

NOT APPROVED. Investigational compound in Phase 3 clinical trials.

⚠️ IMPORTANT: Retatrutide is NOT approved by any regulatory authority for any indication. It is currently in Phase 3 clinical trials. Any products sold online claiming to be retatrutide are likely counterfeit, unverified, and potentially dangerous. Do not purchase from unregulated sources.

Clinical Studies Summary

Phase 2 Retatrutide Trial

Landmark Phase 2 study showing dose-dependent weight loss up to 24.2% at 12mg dose over 48 weeks. 26% of participants lost ≥30% body weight. Gastrointestinal side effects were common but manageable.

N Engl J Med. 2023View on PubMed

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

In a 98-participant substudy of the phase 2 obesity trial, mean relative liver-fat change from baseline at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), and -82.4% (12 mg), versus +0.3% with placebo (all p<0.001 vs placebo). Normal liver fat (<5%) was reached by 27%, 52%, 79%, and 86% of participants at those doses respectively, versus 0% with placebo.

Nat Med. 2024View on PubMed

Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.

Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.

Diabetes Technol Ther. 2025View on PubMed

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.

Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile.

Front Endocrinol (Lausanne). 2025View on PubMed

Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.

Females lost more weight than males when treated with GLP-1RAs for weight reduction. The sex difference in weight reduction became more pronounced as the degree of weight reduction increased. Indications for obesity could magnify this sex difference.

J Diabetes. 2025View on PubMed

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints.

J Clin Endocrinol Metab. 2025View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 3

Approved product

18 of 20 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

PHASE2

Status: Recruiting · 300 participants · Hudson Biotech

Conditions: Obesity

No results postedNCT07467447

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

PHASE3

Status: Active Not Recruiting · 600 participants · Eli Lilly and Company

Conditions: Obesity, Overweight

No results postedNCT07357415

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

PHASE3

Status: Active Not Recruiting · 250 participants · Eli Lilly and Company

Conditions: Obesity, Overweight

No results postedNCT07232719

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

PHASE3

Status: Recruiting · 4,500 participants · Eli Lilly and Company

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease

No results postedNCT07165028

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

PHASE1

Status: Completed · 80 participants · Eli Lilly and Company

Conditions: Type 2 Diabetes Mellitus

No results postedNCT06982846

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

PHASE1

Status: Recruiting · 95 participants · Eli Lilly and Company

Conditions: Diabetes Mellitus, Insulin Sensitivity

No results postedNCT06982859

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

PHASE3

Status: Recruiting · 586 participants · Eli Lilly and Company

Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)

No results postedNCT07035093

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

PHASE3

Status: Active Not Recruiting · 643 participants · Eli Lilly and Company

Conditions: Obesity

No results postedNCT06859268

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

PHASE1

Status: Completed · 30 participants · Eli Lilly and Company

Conditions: Healthy

No results postedNCT06808802

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

PHASE3

Status: Active Not Recruiting · 800 participants · Eli Lilly and Company

Conditions: Obesity

No results postedNCT06662383

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

PHASE3

Status: Active Not Recruiting · 10,000 participants · Eli Lilly and Company

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

No results postedNCT06383390

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

PHASE3

Status: Completed · 537 participants · Eli Lilly and Company

Conditions: Diabetes Type 2

No results postedNCT06354660

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Retatrutide?

Source research-grade Retatrutide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Retatrutide

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What is the current MHRA status of retatrutide?
Are there any UK clinical trials I might be eligible for?
What licensed alternatives exist for my situation today (semaglutide, tirzepatide)?
Why is buying retatrutide from an online seller a risk even compared with other peptides?
How would suspected adverse events from any product be reported?

Quick Facts

Overview

01Evidence snapshot

02Human evidence grade

03Preclinical evidence grade

04Regulatory status

05Approved medical uses

06Unapproved / promotional claims

07Common internet claims

08Claim vs evidence

09Safety uncertainty score

10Known adverse signals

11Drug-interaction uncertainty

12Anti-doping status

13UK legal position

14EU legal position

15What this page cannot tell you

16Last reviewed

17Citation quality score

18Research gaps

19Safer alternatives / established care pathways

20Doctor discussion prompts

Questions to ask a qualified clinician

Discovery & History

Mechanism of Action

Researched Benefits

Claim vs Evidence

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

Phase 2 Retatrutide Trial

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.

Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Registered Trials & Regulatory Status

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Adverse event reports (FDA FAERS)

Looking for Retatrutide?

Frequently Asked Questions